Alaunos Therapeutics (TCRT): Postma Robert W disclosed a 10.0% stake in TCRT and may seek to influence the company 10.0%
Postma Robert W disclosed a 10.0% stake in TCRT and may seek to influence the company.
- 10.0%
- Stake
- 515K
- Shares owned
- Stake as of
- Oct 13, 2026
- Filed
- Oct 15, 2026
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Sep 16, 2026Company filing · Form 8-K · Shareholder rights, Bylaws or charterChanged the rights of its shareholders, and changed its bylaws, charter or fiscal year
- Sep 18, 2026Company filing · Form 8-K · Material agreement, Other newsSigned an important agreement, and reported other company news
- Oct 5, 2026Company filing · Form 8-K · Listing noticeReceived a notice from its stock exchange“As previously disclosed, on April 9, 2026, Alaunos Therapeutics, Inc. (the “Company”) received notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing on the Nasdaq Capital…”
- Oct 13, 2026Company filing · Form 8-K · Material agreement, Acquisition or saleCompleted buying or selling a business or assets, and changed a top executive or board member (and 4 more items)“Appointment of Directors In accordance with the Merger Agreement, on October 13, 2026, effective immediately after the effective time of the Second Merger, Peter Harwin was appointed to the Board as a director.”
What came next
- Oct 15, 20265% stakeFairmount Funds Management LLC filed an activist stake (13D) of 20.0%
- Oct 15, 20265% stakePostma Robert W filed an activist stake (13D) of 10.0%
- Oct 21, 2026Company filing · Form 8-K · Listing noticeReceived a notice from its stock exchange“Background As previously disclosed, on April 9, 2026, Alaunos Therapeutics, Inc. (the “Company”) received a written notice (the “Deficiency Letter”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Capital Market to maintain a minimum…”
How to read SEC Schedule 13D
A Schedule 13D and a Schedule 13G both disclose beneficial ownership of more than 5% of a US company's voting shares. A 13D is the long form, filed by holders who may seek to influence or control the company, and it must state what they intend to do. A 13G is the short form, open only to passive holders and to certain institutions holding in the ordinary course of business, and it asks no question about intent.
Full guide: Schedule 13D vs Schedule 13G: what is the difference?
What else is on file for Alaunos Therapeutics
For Alaunos Therapeutics, OQRO holds 2 fund holdings reports (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its TCRT page.
How this filing works
Explore the data
Common questions
What does this filing report about Alaunos Therapeutics (TCRT) stock?
Postma Robert W disclosed a 10.0% stake in TCRT and may seek to influence the company. Of the company, Schedule 13D (may seek influence).
When did it happen, and when was it made public?
Stake as of: Oct 13, 2026. Filed: Oct 15, 2026.
Is this a trade made on a known date?
No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.
Where does this information come from?
From the SEC Schedule 13D, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Alaunos Therapeutics recently?
For Alaunos Therapeutics, OQRO holds 2 fund holdings reports (13F) dated in the last 90 days. They are listed on the TCRT page.
Does this mean TCRT stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Alaunos Therapeutics
Everything OQRO holds on this company is on its TCRT page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
